Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02757768 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
A Phase 4 study, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 4
- Development phase
- 715
- Enrollment target
NCT02757768 is a Phase 4 study that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 715 participants.
The verdict
NCT02757768, a Phase 4 study, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 715 participants
- Enrollment target
Study Summary
The purpose of the study was to assess the efficacy, safety, and tolerability of mirabegron versus placebo in men with overactive bladder (OAB) symptoms while taking tamsulosin hydrochloride for lower urinary tract symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH).
Interventions
- DRUG Placebo
- DRUG Mirabegron
- DRUG Tamsulosin Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 715 participants |
| Start Date | 2016-06-13 |
| Est. Completion | 2018-09-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02757768
The ClinicalTrials.gov registry entry for NCT02757768 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 715 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02757768 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02757768 about?
NCT02757768 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)". The purpose of the study was to assess the efficacy, safety, and tolerability of mirabegron versus placebo in men with overactive bladder (OAB) symptoms while taking tamsulosin hydrochloride for lower urinary tract symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH).
What is the current status of trial NCT02757768?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 715 participants. The study started on 2016-06-13. Estimated completion is 2018-09-11.
What interventions are being tested in trial NCT02757768?
The interventions under investigation include: Placebo (DRUG), Mirabegron (DRUG), Tamsulosin Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT02757768?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.